Chapter 8. Hepatorenal Syndrome

  1. Donald A. Molony MD2,3 and
  2. Jonathan C. Craig MD, PhD4,5
  1. Andrés Cárdenas MD, MMSc and
  2. Pere Ginès MD

Published Online: 4 MAR 2009

DOI: 10.1002/9781444303391.ch8

Evidence-Based Nephrology

Evidence-Based Nephrology

How to Cite

Cárdenas, A. and Ginès, P. (2008) Hepatorenal Syndrome, in Evidence-Based Nephrology (eds D. A. Molony and J. C. Craig), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303391.ch8

Editor Information

  1. 2

    Division of Renal Disease and Hypertension, University of Texas, USA

  2. 3

    Houston Medical School, Houston, Texas, USA

  3. 4

    School of Public Health, University of Sydney, Australia

  4. 5

    Department of Nephrology, The Children's Hospital at Westmead, Sydney, Australia

Author Information

  1. Liver Unit, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, University of Barcelona, Barcelona, Spain

Publication History

  1. Published Online: 4 MAR 2009
  2. Published Print: 5 DEC 2008

ISBN Information

Print ISBN: 9781405139755

Online ISBN: 9781444303391



  • hepatorenal syndrome (HRS);
  • arterial vasodilation;
  • renin–angiotensin–aldosterone system (RAAS);
  • reduced cardiac output;
  • pharmacological therapy aim;
  • hemodialysis and peritoneal dialysis;
  • nonpharmacological therapy and liver transplantation;
  • extracorporeal albumin dialysis (MARS) system


This chapter contains sections titled:

  • Pathogenesis

  • Clinical features

  • Clinical diagnosis

  • Management

  • Prevention

  • References